Literature DB >> 31790360

Increasing Access to Opioid Use Disorder Treatment: Assessing State Policies and the Evidence Behind Them.

Jesse M Hinde1, Tami L Mark1, Laurel Fuller2, Judith Dey, Jennifer Hayes3.   

Abstract

OBJECTIVE: Combatting the opioid epidemic requires systemic policy changes that address the underutilization of medication-assisted treatment, a therapy that is effective in treating opioid use disorder. In this study, we present approaches used in five states to increase medication-assisted treatment financing and access.
METHOD: We conducted case studies in five U.S. states, interviewing key informants and reviewing the published literature and unpublished documents.
RESULTS: In these states, Medicaid expansion was the most significant lever available to expand financing and access to medication-assisted treatment. Other key levers include Medicaid Section 1115 SUD demonstrations, State Targeted Response to the Opioid Crisis and State Opioid Response grants, state contracting mechanisms, and other state regulations.
CONCLUSIONS: States in this study reported substantial progress in increasing access to medication-assisted treatment, but empirical evidence of their effects is still emerging.

Mesh:

Year:  2019        PMID: 31790360      PMCID: PMC6900991     

Source DB:  PubMed          Journal:  J Stud Alcohol Drugs        ISSN: 1937-1888            Impact factor:   2.582


  10 in total

1.  Fulfilling States' Duty to Evaluate Medicaid Waivers.

Authors:  Kristen Underhill; Atheendar Venkataramani; Kevin G Volpp
Journal:  N Engl J Med       Date:  2018-11-22       Impact factor: 91.245

2.  The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion.

Authors:  Angélica Meinhofer; Allison E Witman
Journal:  J Health Econ       Date:  2018-06-30       Impact factor: 3.883

3.  The Effect of the Affordable Care Act on Uninsured Rates Among Individuals With Mental and Substance Use Disorders.

Authors:  Tami L Mark
Journal:  Psychiatr Serv       Date:  2019-01-03       Impact factor: 3.084

4.  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

Authors:  Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

5.  Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.

Authors:  Christopher M Jones; Elinore F McCance-Katz
Journal:  Addiction       Date:  2018-10-15       Impact factor: 6.526

6.  Insurance Financing Increased For Mental Health Conditions But Not For Substance Use Disorders, 1986-2014.

Authors:  Tami L Mark; Tracy Yee; Katharine R Levit; Jessica Camacho-Cook; Eli Cutler; Christopher D Carroll
Journal:  Health Aff (Millwood)       Date:  2016-06-01       Impact factor: 6.301

7.  Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-11-04       Impact factor: 17.586

8.  Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.

Authors:  Hefei Wen; Jason M Hockenberry; Tyrone F Borders; Benjamin G Druss
Journal:  Med Care       Date:  2017-04       Impact factor: 2.983

9.  Prescribing Practices of Rural Physicians Waivered to Prescribe Buprenorphine.

Authors:  C Holly A Andrilla; Cynthia Coulthard; Davis G Patterson
Journal:  Am J Prev Med       Date:  2018-06       Impact factor: 5.043

10.  Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.

Authors:  Brendan Saloner; Jonathan Levin; Hsien-Yen Chang; Christopher Jones; G Caleb Alexander
Journal:  JAMA Netw Open       Date:  2018-08-03
  10 in total
  1 in total

Review 1.  Financial sustainability of payment models for office-based opioid treatment in outpatient clinics.

Authors:  Dominic Hodgkin; Constance Horgan; Gavin Bart
Journal:  Addict Sci Clin Pract       Date:  2021-07-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.